COMP <GO>
AORT vs MRK // FREE CASH FLOW YIELD
Artivion Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: AORT 3
— MRK 10
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $22.58 (-3.67%) • MKT CAP: $1.14B
fcf-yield
0.07%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AORT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AORT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.40% | 74.80% | -10.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.50% | 20.70% | -16.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 15.3x | +4.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.07% | 3.42% | -3.35 | MRK | /fcf-yield <GO> |
| Operating Margin | 7.60% | 34.30% | -26.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 28.10% | -25.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 1.30% | +12.30 | AORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.46 | 5.19 | -2.73 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 51.7 | +1.90 | AORT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 98.3x | 18.4x | +79.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $361.02B | -$359.88B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AORT REV | MRK REV | AORT GROSS % | MRK GROSS % | AORT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $441.3M | $65.01B | 64.4% | 74.8% | $839.0K | $12.36B |
| FY 2024 | $388.5M | $64.17B | 64.0% | 76.3% | $11.0M | $18.10B |
| FY 2023 | $354.0M | $60.12B | — | — | $18.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AORT // BETA —
MRK // BETA 0.92